Fundraising Fox
/Companies
Sign in

Trivascular

Acquired

Santa Rosa, US · Founded 2007 · Delaware corporation · 5 known investors

Find your way into Trivascular

Sign up to see every warm intro you have to Trivascular

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Trivascular team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Endologix develops medical devices and therapies for treating vascular disease, focusing on interventions such as EVAR (endovascular aneurysm repair) procedures. The company serves physicians and patients with vascular conditions, and offers virtual reality-based procedural training for physicians.

HardwareHealthtechMedical Devices

Founders & leadership

Trivascular was founded in 2007 by Michael V. Chobotov.

MVMichael V. Chobotov
Michael V. ChobotovChief Technology Officer, Board of Directors, Co-founder2012–2016Michael Chobotov is an executive with experience in medical device, aerospace, and automotive sectors, holding more than 60 US patents. He has worked across medical devices, engineering, and early-stage ventures.
SLSHARI L. O'QUINN
SHARI L. O'QUINNVice President, Clinical & Regulatory2016–2017Shari L. O'Quinn is an executive officer at Trivascular with experience leading clinical, regulatory, quality, medical affairs, and health economics functions across multiple regions including the U.S., EMEA, LATAM, and APAC in the medical technology sector.
MR
Michael R. KramerExecutive
KE
KIMBERLEY ELTINGExecutive
CC
CHRISTOPHER CHAVEZExecutive
VKVIVEK K. JAYARAMAN
VIVEK K. JAYARAMANConsultant2016–2016Vivek K. Jayaraman is an executive with experience in healthcare marketing, sales, operations, product management, and business development across pharmaceutical, biotechnology, and medical device sectors. He has held management roles in sales, marketing, and R&D, worked in Asia, and has a background in management consulting advising healthcare companies.
JL
John LiddicoatPresident and Chief Executive Officer
GP
Graham PhillipsChief Operating Officer
CP
Cindy PintoChief Financial Officer
JO
Jorge O'HaraChief Commercial Officer

Board

DA
Douglas A. RoederBoard director
RD
Ryan D. DrantBoard director

Investors · 5

Kaiser Permanente Ventureslisted by Kaiser Permanente VenturesSan Francisco · $2M – $5M

How we know: Kaiser Permanente Ventures's portfolio page · Not right? Tell us

New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M

How we know: a partner's Signal profile · Not right? Tell us

Deerfield Management CompanyreportedNew York

How we know: funding news · press coverage · Not right? Tell us

SR One Capital ManagementinferredRedwood Cityvia Jake Nunn · board

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$17.2M disclosed across 2 rounds · 2012–2015

▶$10MraisedAug 2015 · 5 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • DOUGLAS A. ROEDERDirector
  • SHARI L. O'QUINNExecutive Officer
  • MICHAEL V. CHOBOTOVExecutive Officer
  • MICHAEL R. KRAMERExecutive Officer
  • RYAN D. DRANTDirector
  • DANIEL J. MOOREDirector
  • KIMBERLEY ELTINGExecutive Officer
  • CHRISTOPHER CHAVEZExecutive Officer, Director
  • ROBERT W. THOMASDirector
  • VIVEK K. JAYARAMANExecutive Officer
  • JAMES P. SCOPADirector
  • JAKE R. NUNNDirector
Offering amount
$10M
Amount sold
$10M
First sale
Aug 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.2MraisedFeb 2012 · 22 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas RoederDirector
  • Michael KramerExecutive Officer
  • Jake NunnDirector
  • James ShapiroDirector
  • David KimDirector
  • Michael ChobotovExecutive Officer, Director
  • James ScopaDirector
  • Ryan DrantDirector
  • DANIEL MOOREDirector
  • Robert ThomasExecutive Officer, Director
Offering amount
$7.2M
Amount sold
$7.2M
First sale
Feb 2012
Incorporated
Corporation, Delaware, 2007
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Acquisitions · 1

Early investors' stakes continue via these deals
Nellix Endovascular

Medical device company for aneurysm repair, acquired by Endologix.

Frequently asked questions

What does Trivascular do?
Endologix develops medical devices and therapies for treating vascular disease, focusing on interventions such as EVAR (endovascular aneurysm repair) procedures. The company serves physicians and patients with vascular conditions, and offers virtual reality-based procedural training for physicians.
Who founded Trivascular?
Trivascular was founded by Michael V. Chobotov in 2007.
Who are Trivascular's investors?
Trivascular's investors include 415 Capital, Kaiser Permanente Ventures, New Enterprise Associates (NEA), Deerfield Management Company, SR One Capital Management.
How much funding has Trivascular raised?
Trivascular has disclosed $17.2M raised across 2 rounds.
Where is Trivascular headquartered?
Trivascular is headquartered in Santa Rosa, US.